Thursday 16 October, 2025
Objectives: Longitudinal modelling of tumor lesion diameter data is a useful technique allowing extraction of key metrics of tumor shrinkage, visualization…
Read morePoster: Drug/Disease modeling - Oncology
A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome
Thursday 16 October, 2025
Objectives: Despite intensive research in the field of cancer pathogenesis, today’s modern chemotherapy still relies on empirical values rather than…
Read moreEvaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment
Thursday 16 October, 2025
Objectives: Mathematical models for describing the tumor growth in animals often neglect the relationship between tumor and host organism. To overcome…
Read moreTumor Growth Inhibition Modeling of Onartuzumab in Combination with Erlotinib Does Not Suggest Dose Intensification Would Improve Outcome in Patients with 2nd and 3rd Line Non-small Cell Lung Cancer
Thursday 16 October, 2025
Objectives: The phase III trial OAM4971g comparing onartuzumab (ONT) plus erlotinib vs erlotinib in MET-positive patients with 2nd and 3rd…
Read morePopulation pharmacokinetic analysis of everolimus in patients with solid tumors
Thursday 16 October, 2025
Background: The combination of the mTOR inhibitor everolimus and the multi-kinase inhibitor sorafenib may increase anti-tumor efficacy, therefore the drugs…
Read moreTamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations
Thursday 16 October, 2025
Objectives: Two population pharmacokinetic (PK) models of tamoxifen (TAM) and its principle metabolite endoxifen (ENDX), Model 1, M1, [1] and…
Read moreIn silico simulation study: A comparison of two population pharmacokinetic models of tamoxifen and its major metabolite endoxifen
Thursday 16 October, 2025
Objectives: A high variability in the pharmacokinetics (PK) of tamoxifen and its metabolite endoxifen in estrogen receptor-positive breast cancer patients…
Read moreDevelopment and validation of a model of PSA kinetics predicting prostate cancer aggressiveness during screening
Thursday 16 October, 2025
Objectives: Prostate cancer (PC) is the most common cancer among men [1]. A growing number of cancers is detected by screening….
Read moreModelling and Analysis of Tumor Growth Inhibition for Combination Therapy using Tumor Static Concentration Curves
Thursday 16 October, 2025
Objectives: To develop and analyze a Tumor Growth Inhibition (TGI) model for combination therapy based on experimental data using Tumor Static…
Read moreExtending the Tumor Static Concentration curve to average doses – a combination therapy example using radiation therapy
Thursday 16 October, 2025
Objectives: The recently developed concept of Tumor Static Concentration (TSC) is a valuable modeling tool for the quantitative analysis of combination…
Read more